U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07402356) titled 'VR Pupillometry in Cognitive Impairment' on Jan. 12.
Brief Summary: With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective, single-center, repeated-measures study evaluates whether VR-based eye-tracking pupillometry can provide a practical, non-invasive biomarker of cognitive impairment and its progression over time. Pupil responses are linked to brain arousal systems relevant to cognitive dysfunction, including the locus coeruleus, which is affected early in Alzheimer's disease. Adults aged 18-80 years will be assi...